secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001493152-24-011614
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports 2023 net loss $19.5M; OVATION 2 shows ~30% PFS delay, ~9 months OS improvement
--------------------------------------------------------------------------------

- Net loss $19.5M ($2.16 per share) vs $35.9M ($5.03 per share) in 2022; operating expenses down 17%.
- Cash, investments and accrued interest $15.7M at year end; expects funding into Q4 2024.
- Interim OVATION 2 data: ~30% delay in disease progression or death; ~9 month OS improvement in treatment arm vs control.
- Phase 1/2 trial of IMNN-001 + bevacizumab enrolling at MD Anderson and MSK.
- PlaCCine COVID-19 booster IND submitted; Phase 1 proof-of-concept expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224011614/0001493152-24-011614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224011614/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer